HALAZEPAM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H12ClF3N2O
Molecular Weight	352.738
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C3=CC=CC=C3

InChI

InChIKey=WYCLKVQLVUQKNZ-UHFFFAOYSA-N

InChI=1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2

HIDE SMILES / InChI

Description
Sources: https://www.drugs.com/mtm/paxipam.html
Curator's Comment: description was created based on several sources, including: http://www.wikidoc.org/index.php/Halazepam | http://www.pharmacychoice.com/mdx/drugpoint.cfm?docID=268590&letter=P&type=Trade%20Name&tradeName=Paxipam

Halazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Halazepam is used to relieve anxiety, nervousness, and tension associated with anxiety disorders. Halazepam (Paxipam) is no longer commercially available in the United States. Common adverse effects are: hypotension, nausea, xerostomia, confusion, headache. Alcohol should be avoided while taking Paxipam as it causes drowsiness as well. Medications that also cause drowsiness should not be taken along with Paxipam. These include: Antidepressants, Pain relievers, Seizure medications, Muscle relaxants, Antihistamines, Sleeping pills and sedatives.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; anion channel 203 Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6738302 \| https://www.ncbi.nlm.nih.gov/pubmed/2867566	Positive Allosteric Modulator 186		29.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Anxiety 275 Sources: http://www.psyweb.com/drughtm/jsp/paxipam.jsp	Primary		Approved 8583	PAXIPAM Approved Use Halazepam is used to relieve anxiety, nervousness, and tension associated with anxiety disorders. Launch Date 1981
Seizures 9 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9264104	Primary		Preclinical	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
93 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	HALAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
147 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	NORDAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
137 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534	40 mg 3 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	HALAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
916 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534	40 mg 3 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	NORDAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
347 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	HALAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
796 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	NORDAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
640 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534	40 mg 3 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	HALAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
5863 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534	40 mg 3 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	NORDAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6145534	40 mg 3 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		HALAZEPAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L1M12
ABI Chem	AC1Q4K6Z
AHH Chemical co.,ltd	MT-52276	http://www.ahhchemical.com/product/MT-52276.html
Alsachim	3057	http://www.alsachim.com/product-C4132-glo.bal-view.html
AN PharmaTech	AN-6362
Cayman Chemical	18290
ChemMol	49401011	http://www.chemmol.com/chemmol/49401011.html
Clearsynth	CS-EK-02393	https://www.clearsynth.com/en/CSEK02393.html
Compound Cloud	31640
NovoSeek	31640
Smolecule	S529733	http://www.smolecule.com/products/s529733
Tetrahedron	TS79167
THE BioTek	bt-269284	https://www.thebiotek.com/product/inhibitors/bt-269284
Toronto Research Chemicals	H101500
Toronto Research Chemicals	KIT4845
ZINC	ZINC000000537811	http://zinc15.docking.org/substances/ZINC000000537811

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions.	2010-04-07	20396637
Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder.	2009-07-27	19635161
Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies.	2008-11-04	18983670
[Consumption of inappropriate psychotropic drugs in residential homes for the elderly: comparative study between 2001 and 2006].	2008-09-12	18783709
Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.	2005-12	18360572
Direct injection micellar liquid chromatographic determination of benzodiazepines in serum.	2002-11-25	12401349
Pharmacology, efficacy, and adverse effects of halazepam, a new benzodiazepine.	1982-03-01	6152591
Effects of halazepam and diazepam on the motor coordination of geriatric subjects.	1977-07-19	19262

Patents

Sample Use Guides

In Vivo Use Guide

20-40 mg 3-4 times a day; optimal doses range from 80-160 mg/day

Route of Administration: Oral

In Vitro Use Guide

Competition curves generated by displacing [3H]-flunitrazepam binding, in sections of the forebrain, with halazepam showed IC50 values of 124.45 nM.

Name

Type

Language

HALAZEPAM CIV

Preferred Name

English

HALAZEPAM

Official Name

English

SCH-12041

Code

English

HALAZEPAM [VANDF]

Common Name

English

HALAZEPAM [ORANGE BOOK]

Common Name

English

PAXIPAM

Brand Name

English

SCH 12041

Code

English

7-Chloro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepin-2-one

Systematic Name

English

HALAZEPAM [USAN]

Common Name

English

Halazepam [WHO-DD]

Common Name

English

HALAZEPAM [MI]

Common Name

English

2H-1,4-BENZODIAZEPIN-2-ONE, 7-CHLORO-1,3-DIHYDRO-5-PHENYL-1-(2,2,2-TRIFLUOROETHYL)-

Systematic Name

English

HALAZEPAM [MART.]

Common Name

English

halazepam [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1012